774605-35-5

Basic information

• Product Name: ethyl 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carboxylate
• Synonyms: ethyl 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carboxylate
• CAS NO: 774605-35-5
• Molecular Weight: 328.195
• Mol File: 774605-35-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: ethyl 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carboxylate(774605-35-5)
• EPA Substance Registry System: ethyl 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carboxylate(774605-35-5)

Safety Data

• Hazardous Substances Data: 774605-35-5(Hazardous Substances Data)

Upstream product

• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 7152-15-0 ethyl 4-methyl-3-oxo-pentanoate 
• 3714-77-0 2,6-dichlorobenzaldoxime 
• 25185-95-9 2,6-dichlorobenzaldoxime 
• 6575-28-6 (1E)-2,6-dichlorobenzaldehyde oxime 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 6579-27-7 2,6-Dichloro-N-hydroxybenzenecarboximidoyl chloride 

Downstream Products

• 278597-30-1 [3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methanol 
• 700835-81-0 4-(chloromethyl)-3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole 
• 1268245-11-9 3-(2-(2-chloro-4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)phenyl)cyclopropyl)benzoic acid 
• 1268246-30-5 C₁₅H₁₅Cl₂NO₃ 
• 1268246-31-6 C₁₅H₁₄BrCl₂NO₃ 
• 1268246-32-7 C₁₃H₁₁Cl₂NO₂ 
• 1268246-33-8 C₁₉H₂₅Cl₂NO₂Si 
• 1268246-34-9 C₁₈H₂₃Cl₂NO₃Si 
• 1268246-35-0 C₁₉H₂₇Cl₂NO₃Si 
• 1268246-36-1 2-(3-(2,6-dichlorophenyl)-4-(hydroxymethyl)isoxazol-5-yl)propan-2-ol 
• 1268245-31-3 4-(2-(2-chloro-4-((3-(2,6-dichlorophenyl)-5-(2-hydroxypropan-2-yl)isoxazol-4-yl)methoxy)phenyl)cyclopropyl)benzoic acid 
• 1268246-38-3 C₂₀H₂₉Cl₂NO₃Si 
• 1268246-39-4 C₁₄H₁₅Cl₂NO₃ 
• 1020570-56-2 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carbaldehyde 

Relevant articles and documents

HETEROCYCLIC FXR MODULATORS

The present technology is directed to compounds of formula (I), compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease.

Novel FXR (NR1H4) binding and activity modulating compounds

The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.